Clinical trials: Herpes
Post Herpetic Neuralgia (PHN)
Transcutaneous Auricular Vagus Nerve Stimulation on Post-Herpetic Neuralgia
The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) in the treatment of patients with post-herpetic neuralgia (PHN).
- Trial name
- NCT07123987
- Testing
- transcutaneous auricular vagus nerve stimulation (taVNS), traditional medical treatment for PHN
- Where
- Egypt
- Volunteers
- 34 people
- Sponsor
- Mohamed Hosny Ismail Easa
Herpes Simplex Oral
Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Abreva in the Suppression of Herpes Simplex Virus Eruptions
This will be a randomized, efficacy assessor-blinded, parallel group, pilot study of up to 40 subjects with documented herpes labialis.
- Trial name
- NCT06558838
- Testing
- acyclovir-penciclovir cream, Abreva
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of Utah
Shingles
ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors
This study evaluates if the shingles vaccine works in those persons that receive it before they receive chemotherapy for solid organ tumors.
- Trial name
- NCT02444936
- Testing
- ZOSTAVAX
- Volunteers
- 22 people
- Sponsor
- Louis Stokes VA Medical Center
Shingles, Vaccination Behavior
Nudging Patients to Increase Shingles Vaccination
The purpose of this study is to test whether messages encouraging patients to ask about a Shingrix vaccine at an upcoming appointment will increase Shingrix vaccination rates.
- Conditions
- Shingles, Vaccination Behavior, Behavior, Health
- Trial name
- NCT06238726
- Testing
- Reminder
- Where
- United States
- Volunteers
- 50,786 people
- Sponsor
- Geisinger Clinic
Herpes Simplex
Neonatal Phase 1 Valacyclovir Study
A Phase 1 study that will determine the valacyclovir dose that results in a systemic acyclovir exposure comparable to 10 mg/kg of parenterally administered acyclovir, which is an AUC0-12 of 24,000 ngxhr/mL to 48,000 ngxhr/mL.
- Trial name
- NCT05468619
- Testing
- Valacyclovir
- Where
- 12 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Genital Herpes
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
The purpose of this study is to generate safety and immunogenicity data and establish a proof-of-concept of clinical benefit of the mRNA-1608 vaccine candidate.
- Trial name
- NCT06033261
- Testing
- mRNA-1608, BEXSERO
- Where
- 23 sites in United States
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Mild Cognitive Impairment, Herpes Simplex 1
Valacyclovir for Mild Cognitive Impairment
Anti-viral treatment in Mild Cognitive Impairment (MCI) is a Phase II, placebo-controlled, 52-week trial using oral valacyclovir 4 g/day in 50 HSV seropositive, AD biomarker-positive, amnestic mild cognitive impairment (MCI)…
- Conditions
- Mild Cognitive Impairment, Herpes Simplex 1, Herpes Simplex 2
- Trial name
- VALMCI (NCT04710030)
- Testing
- Valacyclovir hydrochloride 500mg caplet
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- New York State Psychiatric Institute
Herpes Zoster, Herpes Zoster Vaccine
A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults
The purpose of this study was a long-term follow-up of the two studies 110390 and 113077 (ZOSTER-006/022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine…
- Trial name
- NCT02723773
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 161 sites in United States, Australia and 16 more
- Volunteers
- 7,539 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster
The purpose of this study was to assess the safety and immunogenicity of GSK Biologicals' HZ/su vaccine when given on a two-dose schedule to adults aged 50 years and above who had a previous episode of Herpes Zoster (HZ).
- Trial name
- NCT04091451
- Testing
- Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)
- Where
- 3 sites in Russia
- Volunteers
- 1,430 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Simplex Oral
EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions
This will be a randomized, efficacy assessor-blinded, parallel group, pilot study of up to 20 subjects with documented herpes labialis.
- Trial name
- NCT04893577
- Testing
- EDTA, Abreva
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Utah
Alzheimer Disease, Herpes Simplex 1
Anti-viral Therapy in Alzheimer's Disease
Anti-viral therapy in Alzheimer's disease will investigate the efficacy of treating patients with mild Alzheimer's disease with the U.S.A marketed generic anti-viral drug Valtrex (valacyclovir, 500mg oral tablet).
- Conditions
- Alzheimer Disease, Herpes Simplex 1, Herpes Simplex 2
- Trial name
- NCT03282916
- Testing
- Valacyclovir
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Columbia University
Recurrent Herpes Labialis
A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally
Researchers are looking for a better way to treat people who have recurrent herpes labialis, also known as cold sores. This is a type of viral infection that causes redness and blisters on the mouth and lip and that recurs.
- Trial name
- NCT05098938
- Testing
- Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773
- Where
- United States
- Volunteers
- 2,020 people
- Sponsor
- Bayer
Herpes Zoster
A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response
The purpose of this study was to evaluate the long-term immune responses to the Herpes Zoster subunit (HZ/su) vaccine as well as safety up to 7 years after the 2-dose primary vaccination course from study ZOSTER-041…
- Trial name
- NCT04176939
- Testing
- HZ/su vaccine (GSK1437173A)
- Where
- 15 sites in Belgium, Canada and 5 more
- Volunteers
- 68 people
- Sponsor
- GlaxoSmithKline
Neonatal Herpes Simplex Infection
Valacyclovir in Neonatal Herpes Simplex Virus Disease
This is an open-label, single center, pharmacokinetic (PK) study to assess valacyclovir pharmacokinetics and pharmacodynamics in neonates and compare to the pharmacokinetics and pharmacodynamics of the standard of care treatment…
- Trial name
- NCT04448392
- Testing
- Valacyclovir
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Alabama at Birmingham
Herpes Simplex
A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 Years
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of 2 formulations of Herpes Simplex Virus (HSV)-Targeted Immunotherapy (HSVTI) in HSV-2 seronegative ethnic Japanese adults aged 18-40 years.
- Trial name
- TH HSV REC-004 (NCT05989672)
- Testing
- HSVTI Formulation 1, HSVTI Formulation 2
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India
The purpose of this study was to evaluate the humoral immunogenicity and safety of 2 doses of GSK Biologicals' Herpes Zoster subunit vaccine (HZ/su) administered for the prevention of Herpes Zoster (HZ) in adults aged 50 years of…
- Trial name
- NCT05219253
- Testing
- HZ/su
- Where
- 9 sites in India
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Inflammatory Bowel Diseases, Crohn Disease
Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab
Inflammatory bowel disease (IBD) is a chronic inflammatory state of the gastrointestinal tract affecting 1.6-3.1 million people in the United States.
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Herpes Zoster
- Trial name
- NCT03798691
- Testing
- Shingrix
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Wisconsin, Madison
Herpes Zoster Ophthalmicus
Zoster Eye Disease Study
This is a multi-center, randomized, double-masked, placebo-controlled clinical trial of suppressive valacyclovir for one year in immunocompetent study participants with an episode of dendriform epithelial keratitis, stromal…
- Trial name
- ZEDS (NCT03134196)
- Testing
- Masked Oral Valacyclovir
- Where
- 78 sites in United States, Canada
- Volunteers
- 527 people
- Sponsor
- NYU Langone Health
Herpes Zoster
Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years
The purpose of this study was to assess vaccine efficacy (VE), ability to generate immune response and safety of two doses of the recombinant subunit zoster vaccine (RZV) for prevention of Herpes Zoster (HZ) in Chinese adults…
- Trial name
- NCT04869982
- Testing
- RZV
- Where
- 6 sites in China
- Volunteers
- 6,138 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Persistence of Protection by Shingrix
The study plans to learn more about how the shingles vaccine, Shingrix (SRX), successfully prevents shingles in older people. Two vaccines are currently approved by the Food and Drug Administration (FDA) to prevent shingles.
- Trial name
- NCT04169009
- Testing
- Zostavax, Shingrix
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver